38 results about "Hematoporphyrin" patented technology

Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.

A resin composition with a high crystallization rate that contains a polyalkylene furan dicarboxylate resin and a porphyrin compound, and a molded article composed of the resin composition. The polyalkylene furan dicarboxylate resin is preferably a polybutylene furan dicarboxylate resin. The porphyrin compound is preferably hematoporphyrin dihydrochloride. The molded article is obtained by molding the resin composition.

A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, Su has ozone; a penetrating solvent, such as dimethylsulfoxide (''DMSO''); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with cancer, such as lymphoma.

Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.

A method for treating hyperproliferative tissue in a mammal which tissue expresses ABCG2 including the steps of: a) systemically introducing from about 100 to about 1000 mg / kg of body weight of a tyrosine kinase inhibiting compound into the mammal; b) within from about 0.5 to about 24 hours after the introducing in step a) systemically introducing from about 0.05 to about 0.5 μmol per kilogram of body weight of a tumor avid photosensitizing compound, that acts as a substrate for ABC family transport protein, ABCG2 and that has a preferential light absorbance frequency; and c) exposing the hyperproliferative tissue to light at a fluence of from about 50 to about 150 J / cm2 delivered at a rate of from about 5 to about 25 mW / cm2 at the light absorbance frequency. The photosensitizing compound is preferably a tetrapyrollic photosensitizer compound where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pheophorbide including pyropheophorbides, purpurinimide, or bacteriopurpurinimide and derivatives thereof; provided that, the photosensizing compound is not a meso-tetra (3-hydroxyphenyl) derivative, is not a saccharide derivative and is not a hematoporphyrin.

A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (''DMSO''); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with diabetes and obesity.

A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.

The invention discloses an oxygen-carrying and drug-loading self-assembled nano-drug with molecular targeting / sonodynamic therapy (SDT) and a preparation method thereof. According to the nano-drug, erlotinib-modified chitosan (CE) is used as a carrier, then hematoporphyrin (HP) and perfluorooctane bromide (PFOB) are loaded, and CE / PFOB / HP self-assembled nanoparticles (CEPH) are prepared through self-assembly. As a sound sensitizer, the HP can play a role in SDT; and the PFOB carries oxygen and can improve the microenvironment of tumor relative to hypoxia, enhance the SDT effect and overcome the drug resistance of tumor cells to a chemotherapeutic drug Er (erlotinib) under the hypoxia condition. According to the nano-drug, molecular targeted therapy and SDT are combined, the PFOB is used for reversing drug resistance, and tumor cell proliferation can be inhibited to the maximum extent through cooperation of molecular targeted therapy, SDT and PFOB.

The invention discloses a technique for improving phototoxicity effect of hematoporphyrin photosensitizers on tumor cells by preparing the hematoporphyrin photosensitizer / cationic hyperbranched polysaccharide derivative composite nanoparticles. The composite nanoparticles have the following characteristics and have great application prospect in the field of efficient and safe treatment of tumors through photodynamic: 1) the composite nanoparticles have relatively high tumor cell killing efficiency when the concentration of the hematoporphyrin photosensitizers is relatively low, reduction of the dosage of the hematoporphyrin photosensitizers is facilitated, and the safety of the hematoporphyrin photosensitizers for normal cells and tissue under light irradiation is improved; 2) the composite nanoparticles with the particle size ranging from 200 nm to 250 nm have a passive targeting property for tumor tissue, and the safety of the hematoporphyrin photosensitizers for normal cells and tissue is improved; 3) the composite nanoparticles have the electropositivity, can carry the hematoporphyrin photosensitizers to cross over electronegative cell membranes to enter tumor cells, and accordingly, the endocytosis efficiency of the tumor cells for the hematoporphyrin photosensitizers is improved; 4) the preparation condition is mild, the process is simple, the operation is convenient and the cost is low.

The invention discloses a pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide ('DMSO'); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively resolve scar tissue, particularly scar tissue resulting from a burn, and to treat patients with bum-related injuries.

A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with cancer, such as lymphoma.

The invention discloses a magnetic nanoparticle. The magnetic nanoparticle takes Fe3O4 nanoparticles as a core, the surface of the magnetic nanoparticle is coated with mesoporous silica, the surface of the mesoporous silica material is modified with a photosensitizer and embedded alloy nanoparticles, and the photosensitizer is selected from one of hematoporphyrin, hematoporphyrin monomethyl ether,chlorin and 5-aminolevulinic acid. The magnetic nanoparticle prepared by the invention can be used as a nuclear magnetic resonance contrast agent to carry out imaging positioning on tumors, and thennuclear magnetic resonance imaging is used as guidance to carry out photodynamic therapy on the tumors.

A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used effectively to stimulate periapical bone regeneration and for the endodontic treatment of periapical bone abscess, and fibromas, in a patient.

The invention provides a metal hematoporphyrin diether / diester compound and a preparation method thereof. A central metal M of the metal hematoporphyrin diether / diester compound is Fe, Co or Ni. The invention also provides a catalyst for preparing cyclohexane in a catalytic oxidation method and a method for preparing cyclohexane in a catalytic oxidation method by using the catalyst.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of a supramolecular organic framework material to a medicine for removing photodynamic therapy residues. The supramolecular organic framework material is a nano-particle-size water-soluble positive ion type supramolecular organic framework material (SOFs) which is formed by tetrahedral molecules and CB [8] in a water phase through host-guest interaction, and the supramolecular organic framework material realizes high-strength combination and efficient absorption on negatively charged photodynamic therapy medicines (such as chlorin (Ce6), hematoporphyrin (HMTP) and porfimer sodium (Photofrin)). Animal experiments prove that the supramolecular organic framework material can significantly reduce the cumulant of the photodynamic therapy medicine on the surface of animal skin, effectively inhibit the photosensitization of the photodynamic therapy medicine after being irradiated by sunlight, and solve the problem that a patient needs to keep out of light for a long time after photodynamic therapy to a certain extent.

The invention discloses a fabrication method of cellulose membrane of a drug loading breast cancer-targeting magnetic nanoparticles. The method includes the following steps: 1. Grant the folic acid of optical activity by chemical modification, fix the prepared acid on the magnetic hydrogel, which then is be used to absorb hematoporphyrin monomethyl and cancer therapeutic drug, and finally obtain the tumor-targeting nano-drug; 2. Produce cellulose membrane by cultivating acetobacter xylinum and static fermentation, add the tumor-targeting nano-drug solution made in step 1 into the container for the cellulose membrane under dark condition until it's submerged, and carry out vacuum freeze drying after processed by the oscillator. The cellulose membrane of a drug loading tumor-targeting magnetic nanoparticles has high efficient in targeting the breast caner cell and suppressing its growth. At the same time, it can significantly reduce the dosage of conventional photosensitizer. In addition, the transdermal drug delivery would enhance the the drug effects on caner, realizing the controlled-release of the drug and largely lowering the toxic and side effects to healthy tissues.

The invention belongs to the field of organic photochemical synthesis, and particularly relates to a method for preparing a 16-dehydrogenated pregnane dehydropregnenolone acetate compound by using the photosensitized oxidation of a blue LED (light-emitting diode) light source. According to the invention, in the presence of a photosensitizer hematoporphyrin, a catalyst triethylamine and acetate, by taking a blue LED lamp as a light source, false steroid sapogenin di-acetate is subjected to photosensitized oxidation reaction, and then the obtained product is subjected to acid elimination reaction so as to obtain the 16-dehydrogenated pregnane dehydropregnenolone acetate compound. According to the invention, the conversion rate of false steroid sapogenin di-acetate is over 98%, and the yield of the 16-dehydrogenated pregnane dehydropregnenolone acetate compound is up to 82.6%. According to the invention, by replacing a light source high-voltaqe mercury lamp in photosensitized oxidation with the blue LED lamp, on the premise of comparative target product yield, an effect of saving over 40 times of electric energy and a lot of water resources is achieved by using the blue LED lamp. The method disclosed by the invention provides a new technique for green chemistry in the industrial production of steroidal drugs.

The invention provides a swainsonine derivative and a preparation method of a research reagent of the swainsonine derivative. The swainsonine is prepared through the following synthesis steps: a, adding chloroacetic acid and potassium hydroxide by taking swainsonine as a raw material and taking water as a solvent; b, feeding hematoporphyrin into thionyl chloride, and then adding cordycepin; and c, pouring the product obtained in the step a into the product obtained in the step b, and dropwise adding newly prepared potassium ethoxide into the obtained mixture, so that a swainsonine derivative solution is obtained. The swainsonine derivative disclosed by the invention is a product derived on the basis of a swainsonine structure, and by comparing, the difference is as follows: an enriched heterocyclic ring is connected, so that the swainsonine derivative disclosed by the invention has a function of enriching cancer cells, and can allow drugs to tend to parts with tumors but allow the drug concentration of other parts to be little.

The invention discloses a preparation method of an oxygen-carrying and fluorocarbon chain-modified drug and photosensitizer targeted co-delivery nano-composite and application of the nano-composite to preparation of anti-epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) drug-resistant lung cancer drugs. The preparation method of the nano-composite comprises the steps of performing fluorocarbon chain and EGFR-targeted aptamer (Apt) modification on polyamidoamine (PAMAM) to form a nano-drug delivery carrier APF with oxygen carrying capacity and tumor targeting property, and then co-entrapping photosensitizer hematoporphyrin and molecular targeting drug gefitinib to construct the targeting nano-composite APFHG for enhancing the photodynamic therapy effect. The nano-composite overcomes the defect that photodynamic therapy is limited by a tumor anoxic microenvironment and improves the sensitivity of drug-resistant lung cancer cells to EGFR-TKIs, thereby promoting the combined treatment effect of molecular targeted therapy and photodynamic therapy.

The present invention discloses a pharmaceutical formulation and use thereof. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (''DMSO''); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with age-related macular degeneration (''ARMD'').

The invention discloses nanoparticles cooperating with NO gas treatment and enhancing sonodynamic therapy as well as a preparation method and application of the nanoparticles. The nanoparticles are prepared by taking aptamer modified mesoporous silica as a carrier, then loading L-arginine and hematoporphyrin and performing self-assembly. After being modified by an aptamer, the nanoparticles can recognize tumor cells with mutated epidermal growth receptors in a targeted manner; the hematoporphyrin is used as a sound-sensitive agent, generates active oxygen after being subjected to ultrasonic treatment, generates cytotoxicity and can exert the sonodynamic treatment effect of the hematoporphyrin; and the L-arginine is used as an NO donor, NO gas can be generated after cell metabolism, the NO gas and active oxygen further react to generate nitrite ONOO<-> with higher toxicity, and therefore, lung cancer cells are selectively killed. According to the nanoparticles, the aptamer modified carrier is used as a delivery system, NO gas treatment and sonodynamic treatment are combined, the tumor cells are recognized in a targeted mode, and tumor cell proliferation is inhibited to the maximum extent.

The invention discloses a fabrication method of cellulose membrane of a drug loading breast cancer-targeting magnetic nanoparticles. The method includes the following steps: 1. Grant the folic acid of optical activity by chemical modification, fix the prepared acid on the magnetic hydrogel, which then is be used to absorb hematoporphyrin monomethyl and cancer therapeutic drug, and finally obtain the tumor-targeting nano-drug; 2. Produce cellulose membrane by cultivating acetobacter xylinum and static fermentation, add the tumor-targeting nano-drug solution made in step 1 into the container for the cellulose membrane under dark condition until it's submerged, and carry out vacuum freeze drying after processed by the oscillator. The cellulose membrane of a drug loading tumor-targeting magnetic nanoparticles has high efficient in targeting the breast caner cell and suppressing its growth. At the same time, it can significantly reduce the dosage of conventional photosensitizer. In addition, the transdermal drug delivery would enhance the the drug effects on caner, realizing the controlled-release of the drug and largely lowering the toxic and side effects to healthy tissues.

The invention belongs to the field of medicine and pharmacology for increasing sensitivity of chemotherapeutic drugs, and particularly relates to application of a hematoporphyrin-verapamil fragment hematoporphyrin derivative A2 in tolerance reversing and sensitization of breast cancer chemotherapeutic drugs. The hematoporphyrin derivative A2 has different degrees of sensitization of the chemotherapeutic drugs for inhibiting breast cancer cell proliferation, which indicates that the hematoporphyrin derivative A2 can be developed into a sensitizer or a reverse drug-resistant agent of the chemotherapeutic drugs and used for treating breast cancer patients.

The invention discloses a magnetic nanoparticle, the magnetic nanoparticle is Fe 3 o 4 The nanoparticle is the core, and the surface is coated with mesoporous silica, and the surface of the mesoporous silica material is modified with a photosensitizer and an embedded metal nanoparticle, and the photosensitizer is selected from hematoporphyrin, hematoporphyrin monomethyl ether, di Hydroporphine, one of 5-aminolevulinic acid. The magnetic nanoparticle prepared by the invention can be used as a nuclear magnetic resonance contrast agent to image and locate tumors, and then use the nuclear magnetic resonance imaging as a guide to perform photodynamic therapy on tumors.

The invention belongs to the field of medicine and pharmacology for improving chemotherapy drug sensitivity, and particularly relates to application of a hematoporphyrin-verapamil fragment compound A2in reversing the tolerance and sensitization of chemotherapy drugs for osteosarcoma. Different degrees of the sensitization chemotherapeutic drugs of the compound A2 inhibit the proliferation of osteosarcoma cells, which indicates that the compound A2 can be developed into a sensitizer or a reverse drug resistance of the chemotherapeutic drugs and is used for treating osteosarcoma patients.

The invention belongs to the field of medicines for improving the sensitivity of chemotherapeutic drugs, and particularly relates to application of a hematoporphyrin-verapamil fragment hematoporphyrinderivative A2 in tolerance reversion and sensitivity improvement of a colon cancer chemotherapeutic drug. The hematoporphyrin derivative A2 has the effect of improving the sensitivity of the chemotherapeutic drug for inhibiting the proliferation of colon cancer cells to different degrees, and it is indicated that the hematoporphyrin derivative A2 can be developed into a sensitizer or a drug tolerance reversion agent of the chemotherapeutic drug and is used for treating patients with colon cancer.

The invention discloses a novel material containing biomimetic enzymes. The material uses PEI to synthesize gold nanoparticles. PEI is a positively charged polymer rich in imine groups and amine groups and has good water solubility. It can be combined with chloroauric acid Coordination of gold ions in the PEI, using the reduction of PEI branched chain amino groups to prepare gold nanoparticles with uniform particle size and stability. In addition, because the PEI molecule contains amino groups, it is easy to form an amide bond with Hemin, so that the Hemin molecule is connected to the PEI containing gold nanoparticles, and through centrifugation and separation and purification, a hematoporphyrin biomimetic material wrapped with gold nanoparticles is obtained. . This new type of material not only has the high catalytic performance of biomimetic enzymes, it can be used as an electrochemical probe to detect the content of pollutants in water, such as hydrogen peroxide, catechol, etc. On the other hand, due to the porous structure of the material itself, it can Dye molecules, such as methyl orange, rhodamine, etc., are adsorbed to protect the ecological environment.